World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 7 October 2014
Main ID:  EUCTR2005-005326-30-BE
Date of registration: 01/03/2006
Prospective Registration: Yes
Primary sponsor: sanofi-aventis recherche & développement
Public title: International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOX
Scientific title: International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOX
Date of first enrolment: 24/04/2006
Target sample size: 700
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005326-30
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: yes Other specify the comparator: Idraparinux sodium  
Phase: 
Countries of recruitment
Austria Belgium Czech Republic Denmark Italy Spain
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Confirmed acute symptomatic DVT of the lower limbs.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1-Exclusion criteria before initial randomization:
Legal lower age limitations (country specific).
Creatinine clearance < 30 mL/min.
Severe hepatic disease.
Bacterial endocarditis.
Active bleeding or high risk for bleeding.
Uncontrolled hypertension: systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg.
Pregnancy or childbearing potential without proper contraceptive measures.
Breastfeeding.
Known allergy to idraparinux, SSR126517E, or egg proteins.
-Criteria related to study methodology
Written informed consent not signed.
Indication of prolonged anticoagulation for other reason than DVT of the lower limbs.
Symtomatic pulmonary embolism (PE).
Any administration or intended use of a fibrinolytic agent, thrombectomy, insertion of a caval filter, to treat the current episode of DVT.
More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW) Heparin, fondaparinux or initiation of VKA treatment prior to randomization
Life expectancy < 6 months.
Participation in another pharmacotherapeutic study within the prior 30 days.
Impossibility to meet protocol requirements.

2-Exclusion criteria at the end of the 6-month treatment period for participation in the avidin neutralizing effect assessment
Patient receiving open-label avidin during the study.
Patient requiring more than 6-month anticoagulant treatment.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Patients with confirmed acute symptomatic DVT of the lower limbs
MedDRA version: 8.1 Level: PT Classification code 10051055
Intervention(s)

Product Name: Idraparinux
Product Code: SR34006
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Idraparinux sodium
CAS Number: 149920-56-9
Current Sponsor code: SR34006
Other descriptive name: SR34006A
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-

Product Name: Biotinylated Idraparinux
Product Code: SSR126517
Pharmaceutical Form: Solution for injection
CAS Number: 405159-59-3
Current Sponsor code: SSR126517
Other descriptive name: SSR126517E
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 6-

Product Name: Avidin
Product Code: SSR29261
Pharmaceutical Form: Powder for injection*
CAS Number: 1405-69-2
Current Sponsor code: SSR29261
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Powder for injection*
Route of administration of the placebo: Intravenous drip use (Noncurrent)

Primary Outcome(s)
Secondary Objective: To assess the time course to steady state achievement of SSR126517E/SR34006.
To provide safety and efficacy data on biotinylated idraparinux (SSR126517E) compared to idraparinux (SR34006).
Main Objective: -Primary objective of the bioequipotency assessment:
To demonstrate the bioequipotency of biotinylated idraparinux (SSR126517E) and idraparinux (SR34006) at steady state, in patients, with acute symptomatic DVT, as assessed by anti-Xa activity.
-Primary objective of the avidin neutralizing effect assessment:
To demonstrate the neutralizing effect of avidin (SSR29261) on anti-Xa activity induced by biotinylated idraparinux (SSR126517E).
Primary end point(s): PRIMARY ENDPOINTS AND MAIN SECONDARY ENDPOINTS:
1-Bioequipotency assessment, avidin neutralizing effect assessment and time course to steady state achievement
The PD variable is the anti-Xa activity, measured without excess of antithrombin (AT), relative to the maximal effect in a pool of plasma from healthy volunteers.
The PK variable is the anti-Xa activity, measured with excess of AT.
2-Safety assessment
The main two-safety outcome events are bleeding, reported as either AE or SAE, and validated by the CIAC, and death (cause of death validated by the CIAC).
3-Efficacy assessment
The main efficacy outcome is symptomatic recurrent DVT/PE (fatal or not), as validated by the CIAC.
Secondary Outcome(s)
Secondary ID(s)
2005-005326-30-AT
EFC5945
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history